The Food & Drug Administration (FDA) has awarded The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.   The study—entitled “Improving the Efficiency of Regulatory Decisions for Biosimilars and Interchangeable Biosimilars by Leveraging Real-World Data to Produce Real-World Evidence”—will evaluate the safety and effectiveness of b...